Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 23.50 (1.38%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,729.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Struggling Miners Offset Buoyant Admiral

Wed, 15th Aug 2018 12:02

LONDON (Alliance News) - Reversing some early gains, stocks in London had tumbled firmly into the red by midday on Wednesday with miners falling and apprehension around Turkey remaining.The pound, meanwhile, was trending lower despite UK inflation accelerating for the first time since November last year.The FTSE 100 down 0.8%, or 64.14 points, at 7,547.50 - having hit a high of 7,632.07 in early trade Wednesday. The FTSE 250 was down 0.4%, or 73.60 points, at 20,436.16. The AIM All-Share was 0.2% lower at 1,085.60.In mainland Europe, the CAC 40 in Paris was down 0.4% while the DAX 30 in Frankfurt was down 0.1% at midday. In the US, stocks are pointed to follow Europe with a lower start. The Dow Jones is called down 0.3%, while the S&P 500 and the Nasdaq are seen opening 0.2% lower. Focus in the US on Wednesday is on retail sales at 1330 BST. Before this, at 1200 BST, are MBA mortgage applications."The problem for risk appetite is that the bounce by Turkey's lira largely reflected profits being taken. It was not due to effectiveness of the central bank's piecemeal and relatively small dollar-liquidity moves," said Ken Odeluga, market analyst at City Index.The lira on Monday hit record lows, before steadying on Tuesday but experiencing shaky trade overnight."Turkey's lira lost all Wednesday gains at one point, following Tuesday's bounce of more than 8%. It is now firmer again, though clearly volatile. It's uncertain whether the rebound will be sustained. " added Odeluga.Inflaming the situation, Turkey increased tariffs on US-made products ranging from cars to tobacco on Wednesday. The new measures, published in the official gazette, go into effect immediately and include a 140% hike in US-made alcoholic beverages and an increase of 120% on US cars.In the UK, the pound was lower as the Office for National Statistics on Wednesday showed UK inflation accelerated for the first time in eight months in July.Consumer prices climbed 2.5% year-on-year in July, as expected by economists, but slightly faster than the 2.4% increase in June. Core inflation that excludes energy, food, alcoholic beverages and tobacco, held steady at 1.9% in July.However, analysts expect inflation growth to trail off in the short-term."Barring any further gyrations in oil prices, we think July's figure represents a peak, and we expect CPI to begin trending downwards over the next few months gradually," said James Smith, developed markets economist at ING.Smith continued: "The impact of the pound's post-Brexit plunge is continuing to fade - prices have more-or-less adjusted to the weaker level of sterling - and this is seeing core goods inflation slow. We expect this to keep core CPI close to 2% for the foreseeable future, although there's a risk that this slips lower."Sterling was quoted at USD1.2709 Wednesday midday, having traded around USD1.2729 prior to the release of the data and lower than USD1.2736 at the London equities close on Tuesday.Hindering the FTSE 100 on Wednesday were blue-chip miners, with Antofagasta, Anglo American and Glencore down 3.5%, 3.4% and 3.0%, respectively."The price of copper has this week hit a 13-month low following a sharp slowdown in China's fixed-asset investment growth. This news, together with waning investor appetite for riskier assets, has unsurprisingly put a dent in the mining sector," explained Russ Mould, investment director at AJ Bell."Copper is widely considered to be a bellwether for the global economy and so a weak price is cause for concern," he added.The FTSE 350 Mining Sector Index - which houses many of London's commodity stocks - was down 2.6% at midday.Unable to offset these losses was Admiral's 3.4% rise, as its interim results beat market forecasts.The FTSE 100-listed insurer posted a 9.1% increase in pretax profit to GBP211.0 million from GBP193.4 million the year before. Revenue increased 14% to GBP1.66 billion from GBP1.45 billion.The company is proposing an interim dividend of 60.0 pence per share, a 7.1% increase year-on-year from 56.0p paid the previous year.Chief Executive Officer David Stevens said: "Zut alors. Nos operations europeennes sont rentables! Or probably more accurately, given that over half of our European customers are Italian - le nostre compagnie Europee sono in profitto. Moreover, the European insurers delivered overall profitability whilst growing the business by almost a fifth in a year."The European insurance business - comprising operations in Spain, Italy and France - posted its first ever profit of GBP2.5 million, versus a GBP5 million loss a year ago.GlaxoSmithKline gained 1.5% after the drugmaker said ViiV Healthcare - its HIV treatment joint venture - saw its Atlas study meet its primary endpoint.Phase 3 of the study - for a long-acting, injectable two-drug regimen for the treatment of HIV - showed long-acting cabotegravir and rilpivirine, injected once a month, had similar efficacy to a standard of care, daily, oral three-drug regimen at Week 48.The injectable treatment regimen met the primary endpoint for non-inferiority, Glaxo said. Overall safety, virologic response and drug resistance results for the injectable regimen were consistent with results from the phase II Latte and Latte-2 studies.Sat atop the mid-cap FTSE 250 was Hikma Pharmaceuticals, up 6.3% as it upgraded its revenue guidance for two of its units.Hikma on Wednesday said pretax profit for the six months to the end of June totalled USD141.0 million, up from USD100.0 million reported for the same period a year earlier, as revenue climbed 11% to USD989.0 million from USD895.0 million. Looking ahead, Hikma said it now expects revenue for its Injectables division for 2018 to come in between USD775 million and USD825 million. Previously, Hikma had targeted the unit to achieve revenue in a range of USD750 million to USD800 million.Hikma also now expects the Generics division to deliver revenue in the range of USD600 million to USD650 million, up from the USD550 million to USD600 million range forecast in mid-May.Balfour Beatty, up 2.9%, boosted its interim payout by a third.The construction company multiplied its pretax profit to GBP50 million from just GBP12 million the year before. Revenue decreased 9.4% to GBP3.84 billion from GBP4.20 billion.While revenue fell, the company said, gross profit increased and overheads declined, resulting in improved profitability.Balfour is proposing an interim dividend increase of 33% to 1.6p per share from 1.2p last year.Kaz Minerals was slumped at the bottom of the mid-caps, down 6.7% as the copper miner was dented along with blue-chip peers by tumbling commodity prices.
More News
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 17:10

Miners, personal goods stocks drag FTSE 100 to two-week low

Burberry slips on rating downgrade

*

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 12:10

LONDON MARKET MIDDAY: Stocks down before Fed minutes and US PMI data

(Alliance News) - Stock prices in London were down at midday on Wednesday, in cautious trade ahead of key US data and central bank minutes in the afternoon.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
29 Dec 2023 13:01

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.

Read more
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.